2
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Interventional
1
Sponsor
Conditions
Multiple Sclerosis
2
Carcinoma in Situ
2
Multiple Sclerosis, Relapsing-Remitting
1
Multiple Sclerosis, Chronic Progressive
1
Interventions
Surveys and Questionnaires
543
Blood Specimen Collection
446
Surgical Procedures, Operative
164
Observation
152
Drug Therapy
142
Radiotherapy
141
Interviews as Topic
139
Gene Expression Profiling
129
Biopsy
117
Magnetic Resonance Spectroscopy
116
Immunohistochemistry
112
Data Collection
95
Polymerase Chain Reaction
87
Specimen Handling
81
Amplified Fragment Length Polymorphism Analysis
81
Bevacizumab
78
Microarray Analysis
76
Flow Cytometry
69
Neoadjuvant Therapy
68
Watchful Waiting
66
Magnetic Resonance Imaging
65
Immune Checkpoint Inhibitors
61
Nivolumab
60
Immunotherapy
57
Therapeutics
55
Reverse Transcriptase Polymerase Chain Reaction
52
pembrolizumab
50
Ultrasonography
47
Positron Emission Tomography Computed Tomography
47
Hematologic Tests
46
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Observational
×
Interferon beta-1b
×
Clear all
NCT02486640
2023-07-24
BETAPREDICT
Bayer
Completed
162 enrolled
NCT03134573
2019-03-26
PROmyBETAapp
Bayer
Completed
96 enrolled